ClinVar Miner

Submissions for variant NM_033380.3(COL4A5):c.4964T>G (p.Leu1655Arg) (rs104886303)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000440813 SCV000515887 pathogenic not provided 2019-01-17 criteria provided, single submitter clinical testing The L1655R missense variant in the COL4A5 gene has been reported previously in association with Alportsyndrome (Barker et al., 1996; Barker et al., 2001; Martin et al., 1998). Individuals previously reported with this variant were noted to have relatively mild Alport syndrome with onset in the 4th or 5th decade, with late hearing loss approximately 10 years after the onset of renal failure (Barker et al, 1996). The L1655R substitution was not observed in approximately 6,500individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating itis not a common benign variant in these populations. Furthermore, other missense variants in nearbyresidues (S1659G, S1659N) have been reported in association with Alport syndrome in the Human GeneMutation Database (Stenson et al., 2014). L1655R is a non-conservative amino acid substitution resulting inthe replacement of a neutral non-polar Leucine residue with a positively charged Arginine residue in the NC1domain. Therefore, we interpret L1655R to be pathogenic.
Athena Diagnostics Inc RCV000440813 SCV000612998 pathogenic not provided 2017-06-09 criteria provided, single submitter clinical testing
Fulgent Genetics,Fulgent Genetics RCV000011212 SCV000893815 pathogenic Alport syndrome 1, X-linked recessive 2018-10-31 criteria provided, single submitter clinical testing
Invitae RCV000440813 SCV000965555 pathogenic not provided 2019-11-20 criteria provided, single submitter clinical testing This sequence change replaces leucine with arginine at codon 1649 of the COL4A5 protein (p.Leu1649Arg). The leucine residue is highly conserved and there is a moderate physicochemical difference between leucine and arginine. This variant is present in population databases (rs104886303, ExAC 0.002%). This variant has been observed in individual(s) with Alport syndrome (PMID: 8651292, 23572034). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 10466). This variant has been reported to affect COL4A5 protein function (PMID: 18083113). For these reasons, this variant has been classified as Pathogenic.
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV000011212 SCV001156656 pathogenic Alport syndrome 1, X-linked recessive 2019-02-28 criteria provided, single submitter clinical testing The COL4A5 c.4946T>G; p.Leu1649Arg variant (rs104886303), also reported as Leu1655Arg, has been described in multiple individuals and families affected with Alport syndrome and is associated with a mild phenotype presenting in adulthood (Barker 1996, Barker 2001, Kobayashi 2008, Martin 1998, Pont-Kingdon 2009). It is reported as pathogenic by multiple sources in ClinVar (Variation ID: 10466), and is absent from general population databases (Exome Variant Server and Genome Aggregation Database), indicating it is not a common polymorphism. The leucine at codon 1649 is highly conserved, and computational algorithms (PolyPhen-2, SIFT) predict that this variant is deleterious. In agreement with this, in vitro analysis of the variant protein demonstrates defective trimerization, leading to secretion of a less stable monomeric alpha chain (Kobayashi 2008). Based on available information, this variant is considered pathogenic. REFERENCES Barker D et al. A mutation causing Alport syndrome with tardive hearing loss is common in the western United States. Am J Hum Genet. 1996 Jun;58(6):1157-65. Barker D et al. Efficient detection of Alport syndrome COL4A5 mutations with multiplex genomic PCR-SSCP. Am J Med Genet. 2001 Jan 15;98(2):148-60. Kobayashi T et al. Mutational analysis of type IV collagen alpha5 chain, with respect to heterotrimer formation. Biochem Biophys Res Commun. 2008 Feb 1;366(1):60-5. Martin P et al. High mutation detection rate in the COL4A5 collagen gene in suspected Alport syndrome using PCR and direct DNA sequencing. J Am Soc Nephrol. 1998 Dec;9(12):2291-301. Pont-Kingdon G et al. Molecular testing for adult type Alport syndrome. BMC Nephrol. 2009 Nov 17;10:38.
UNC Molecular Genetics Laboratory,University of North Carolina at Chapel Hill RCV001195698 SCV001366102 pathogenic Alport syndrome 2018-10-31 criteria provided, single submitter clinical testing
OMIM RCV000011212 SCV000031439 pathogenic Alport syndrome 1, X-linked recessive 1996-06-01 no assertion criteria provided literature only
Research and Development, ARUP Laboratories RCV000011212 SCV000042326 moderate Alport syndrome 1, X-linked recessive 2012-12-04 no assertion criteria provided clinical testing Converted during submission to Pathogenic.
GeneReviews RCV000011212 SCV000057825 pathologic Alport syndrome 1, X-linked recessive 2013-02-28 no assertion criteria provided curation Converted during submission to Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.